Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
Purpose
We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.
Condition
- Diaphragm Injury
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patients undergoing esophagectomy
Exclusion Criteria
- Patients with more than mild pulmonary dysfunction - Patients with any neuromuscular disease that might compromise diaphragm function - Patients with abnormal liver or kidney function - Patients taking any immunosuppressant medication (including prednisone) or antifungal medications - History of tuberculosis - Weight loss of >5% of body weight over previous 6 months - Pregnancy
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Prevention
- Masking
- Single (Participant)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Tofacitinib |
Patient will receive two days treatment with tofacitinib prior to the surgery. |
|
|
Placebo Comparator Placebo |
Patient will receive two days treatment with placebo prior to the surgery. |
|
Recruiting Locations
Stanford University Medical Center
Stanford, California 94305
Stanford, California 94305
More Details
- Status
- Recruiting
- Sponsor
- Stanford University